ArQule, Inc. Sustainability Profile
ArQule, Inc., a prominent biopharmaceutical company headquartered in the United States, is dedicated to advancing innovative therapies for cancer and other serious diseases. Founded in 1990, ArQule has established itself as a leader in the development of targeted therapies, particularly in the field of oncology. The company’s core offerings include a range of proprietary drug candidates that leverage its unique drug discovery platform, setting it apart in a competitive market. With a strong focus on precision medicine, ArQule has achieved significant milestones, including partnerships with major pharmaceutical firms and successful clinical trials. Its commitment to scientific excellence and patient-centric solutions has positioned ArQule as a notable player in the biopharmaceutical industry, driving advancements that aim to improve patient outcomes globally.
DitchCarbon Score
How does ArQule, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ArQule, Inc.'s score of 94 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ArQule, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Merck & Co., Inc., and therefore, any climate commitments or emissions data may be influenced by its parent organisation's initiatives. ArQule's climate commitments are aligned with those of Merck & Co., Inc., which has established various reduction targets and initiatives. However, specific reduction targets or achievements for ArQule itself have not been disclosed. The emissions data and performance metrics are cascaded from Merck & Co., Inc., which is responsible for the overarching climate strategy and reporting. As a subsidiary, ArQule may benefit from Merck's participation in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which aim to drive significant reductions in greenhouse gas emissions across their operations. However, without specific data or targets attributed directly to ArQule, the company's individual climate impact remains unclear.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,532,400,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 5,760,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is ArQule, Inc.'s Industry?
How Carbon Intensive is ArQule, Inc.'s Location?
ArQule, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
ArQule, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
